RxDoctor Payments Data

Jeffrey Garrett, MD

Interventional Cardiology · Pittsburgh, PANPI 1861456527

Payments from drug & device makers

$801in general payments, 2019–2025

Across 67 payments — averaging $11.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$433
  • Johnson & Johnson$125
  • E.r. Squibb & Sons, L.L.C.$95
  • Cvrx, Inc.$56
  • Atricure, Inc.$24
  • Tactile Systems Technology Inc$17
  • plus $51 from 4 others

What the payments were for

  • Food & beverage$78398%
  • Education$192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$801 in reported general payments places this provider in the 5th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$100,652
Medicare patients
497
Services billed
1,359

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban236$227,845
XareltoRivaroxaban147$149,958
EntrestoSacubitril/Valsartan109$131,104
Repatha SureclickEvolocumab99$87,186
JardianceEmpagliflozin40$54,330
MultaqDronedarone Hcl25$25,868
FarxigaDapagliflozin Propanediol16$15,527
BrilintaTicagrelor20$15,356
TrulicityDulaglutide15$14,960
Repatha SyringeEvolocumab12$10,155
MyrbetriqMirabegron13$9,647
Repatha PushtronexEvolocumab13$8,714
Atorvastatin Calcium650$6,834
Valsartan165$5,784
Ranolazine ErRanolazine38$5,583

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$125$149,958147 claims
NovartisEntresto$433$131,104109 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →